| Model results suggest that adding canagliflozin 100 mg to SoC can improve patient outcomes while reducing overall net costs from the NHS perspective in England (Diabetes Therapy)
We suggest pragmatic options for screening of GDM in a pandemic setting based on blood tests, and risk calculators applied to underlying risk factors (European Journal of Endocrinology)
SGLT2 inhibitor administration yielded minimal effects on ARR and did not increase false-negative results in PA screening in patients with diabetes and hypertension more than 2 months after administration (BMC Endocrine Disorders)
Circulating ANGPTL2 levels are an independent risk factor for DFUs. This suggests that ANGPTL2 may play important roles in the development of DFUs, a possibility that needs to investigated in prospective studies (BMC Endocrine Disorders)
This systematic review and meta-analysis shows clinical benefits with the glucose lowering medications in patients with T2DM who fast during Ramadan (Diabetes Research and Clinical Practice)
Changes in diabetes-related protocols and new technology can be deployed in the inpatient setting to potentially improve healthcare worker and patient safety; however, one must weigh the risks and benefits of implementation during a pandemic (Current Diabetes Reports)
| 
